Fig. 6.

OVA treatment increases whole lung pGSK content and decreases whole lung GSK-3β kinase activity. A: lungs from PBS or OVA-sensitized mice were homogenized, and 20 μg of protein was assessed by immunoblotting for α-actin, β-actin, phospho-Ser⁹, and total GSK-3β. For MHC, 50 μg of protein was processed. In addition, GSK-3β was immunoprecipitated from 1 mg of soluble lung protein, and GSK-3β activity was assessed using recombinant tau as a substrate. Changes in phosphorylation were not due to a difference in the GSK-3β content of immunoprecipitates. B: group mean data for pixel densitometry scans using NIH ImageJ software (n = 3; *P < 0.05, ANOVA).